Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential

The non–vitamin K antagonist oral anticoagulant rivaroxaban is used in several thromboembolic disorders. Rivaroxaban is eliminated via both metabolic degradation and renal elimination as unchanged drug. Therefore, renal and hepatic impairment may reduce rivaroxaban clearance, and medications inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Willmann, Stefan, Coboeken, Katrin, Kapsa, Stefanie, Thelen, Kirstin, Mundhenke, Markus, Fischer, Kerstin, Hügl, Burkhard, Mück, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Physiologically Based Pharmacokinetic Modeling
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048900/
https://www.ncbi.nlm.nih.gov/pubmed/33205449
http://dx.doi.org/10.1002/jcph.1784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048900/
https://www.ncbi.nlm.nih.gov/pubmed/33205449
http://dx.doi.org/10.1002/jcph.1784

Ejemplares similares